Evidence map›Paper›PMID 37874617›Full record

ArticleeLife2023

Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.

Xiang Wang, Vitaliy V Bondar, Oliver B Davis, Michael T Maloney, Maayan Agam, Marcus Y Chin, Audrey Cheuk-Nga Ho, Rajarshi Ghosh, Dara E Leto, David Joy and 6 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. LRRK2: Molecular Mechanisms in Parkinson's Disease.International journal of molecular sciences · 2026
    Review
  5. Review
  6. The structural basis for LRRK2's activation and autoinhibition.bioRxiv : the preprint server for biology · 2026
    Article
  7. Elucidating the molecular interplay between LRRK2 and Rab GTPases.bioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Rab12 is a regulator of mitophagy and mitochondrial homeostasis.bioRxiv : the preprint server for biology · 2026
    Article
  10. Review
  11. Article
  12. Lysosomal swelling triggers LRRK2 activity.bioRxiv : the preprint server for biology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Common PD-RiskbioRxiv : the preprint server for biology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Xiang Wang *Denali Therapeutics, South San Francisco, United States.ORCID 0000-0001-5134-1292
Vitaliy V Bondar *Denali Therapeutics, South San Francisco, United States.
Oliver B DavisDenali Therapeutics, South San Francisco, United States.ORCID 0000-0002-3622-8651
Michael T MaloneyDenali Therapeutics, South San Francisco, United States.
Maayan AgamDenali Therapeutics, South San Francisco, United States.
Marcus Y ChinDenali Therapeutics, South San Francisco, United States.
Audrey Cheuk-Nga HoDenali Therapeutics, South San Francisco, United States.
Rajarshi GhoshDenali Therapeutics, South San Francisco, United States.
Dara E LetoDenali Therapeutics, South San Francisco, United States.
David JoyDenali Therapeutics, South San Francisco, United States.ORCID 0000-0001-9941-9538
Meredith E K CalvertDenali Therapeutics, South San Francisco, United States.
Joseph W LewcockDenali Therapeutics, South San Francisco, United States.ORCID 0000-0003-3012-7881
Gilbert Di PaoloDenali Therapeutics, South San Francisco, United States.
Robert G ThorneDenali Therapeutics, South San Francisco, United States.
Zachary K SweeneyDenali Therapeutics, South San Francisco, United States.
Anastasia G HenryDenali Therapeutics, South San Francisco, United States.ORCID 0000-0002-8124-5477
Denali Therapeutics (United States) · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) variants associated with Parkinson's disease (PD) and Crohn's disease lead to increased phosphorylation of its Rab substrates. While it has been recently shown that perturbations in cellular homeostasis including lysosomal damage can increase LRRK2 activity and localization to lysosomes, the molecular mechanisms by which LRRK2 activity is regulated have remained poorly defined. We performed a targeted siRNA screen to identify regulators of LRRK2 activity and identified Rab12 as a novel modulator of LRRK2-dependent phosphorylation of one of its substrates, Rab10. Using a combination of imaging and immunopurification methods to isolate lysosomes, we demonstrated that Rab12 is actively recruited to damaged lysosomes and leads to a local and LRRK2-dependent increase in Rab10 phosphorylation. PD-linked variants, including LRRK2 R1441G and VPS35 D620N, lead to increased recruitment of LRRK2 to the lysosome and a local elevation in lysosomal levels of pT73 Rab10. Together, these data suggest a conserved mechanism by which Rab12, in response to damage or expression of PD-associated variants, facilitates the recruitment of LRRK2 and phosphorylation of its Rab substrate(s) at the lysosome.

Indexed as

Biological PhenomenaLysosomesrab GTP-Binding ProteinsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationPhosphorylationLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanRab12 protein, humanrab GTP-Binding Proteinscell biologyhumanLRRK2lysosomal damageParkinson's diseaseRab12

Identifiers

PMID37874617
PMCPMC10708889
OpenAlexW4387893870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.